Viking Therapeutics (VKTX) Q2 2026 earnings review
Viking advances its obesity trials, but its cash shrinks fast
Viking Therapeutics, a clinical-stage developer of obesity drugs, slowed its quarterly spending while its cash balance kept shrinking at the same pace. Operating expenses fell 19% from the first quarter to $133 million as drug manufacturing bills eased, and chief executive Brian Lian kept all four obesity clinical trials on schedule. Even so, cash and short-term investments dropped by $101 million to $502 million, leaving five quarters of funding at the current pace by our math.
| Cash and short-term investments | $502M down $101M from last quarter |
|---|---|
| Research and development expenses | $115.8M down 23% from last quarter |
| Net loss per share | $1.10 $0.58 a year ago |
| Cash runway outlook | Unchanged management projects cash into 2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because lower quarterly expenses did not slow the actual cash drain. Management eased one cost concern by noting that the upcoming Phase 3 trials for its obesity pill will be roughly 75% smaller than its injectable trials. One caution: Lian revealed that the Phase 1 maintenance study compressed the initial dose ramp-up to reach higher doses faster, which could inflate stomach side effects when data arrives this quarter.
The question now is whether quarterly cash burn can drop enough to fund the company into 2028 as finance chief Greg Zante plans. One view is that peak spending on the injectable Phase 3 trials has passed; the other is that starting two oral Phase 3 trials and paying supplier commitments will force a capital raise before the 2027 Phase 3 readouts. The cash flow statement in the upcoming quarterly filing and fourth-quarter spending will settle it.
🐂 Bull Case
Trial Spending Dropped and Oral Studies Cost Less
Viking is a biotechnology company developing treatments for obesity, so it has no product sales and its main financial measure is research spending. Finance chief Greg Zante said on the call regarding cash burn, "I think this is really the heaviest usage period." Total operating expenses fell 19.2% from the first quarter to $132.6 million as drug manufacturing bills eased.
The company also gave new detail on the upcoming Phase 3 trials for the pill version of VK2735, its lead weight-loss drug. Chief executive Brian Lian said the two oral studies will be "75% smaller than the VANQUISH study", the 5,500-patient injectable program. Lian added, "It's quite a bit smaller, so the expense will be quite a bit lower as a result."
What to watch: research and development expenses in the third and fourth quarters. A further decline even as the oral Phase 3 trials start in the fourth quarter would confirm that quarterly spending has peaked.
Four Obesity Clinical Programs Advance on Schedule
The drug developer wants to offer patients multiple ways to lose weight and keep it off. Its main drug, VK2735, mimics two gut hormones (GLP-1 and GIP) that regulate appetite and blood sugar. During the quarter, Viking switched patients in its two Phase 3 VANQUISH injectable trials from vials and syringes to auto-injector pens. Lian noted regarding the switch, "Your clinic visits dropped from 4 per month to 1 per month."
Fewer clinic visits make it easier for the 5,500 enrolled patients to stay in the 78-week studies. Meanwhile, the company started a Phase 1 human trial of VK3019, a new obesity drug targeting amylin and calcitonin receptors that control hunger. It also remained on schedule to report Phase 1 maintenance dosing results in the third quarter and start Phase 3 oral trials in the fourth quarter.
What to watch: the Phase 1 maintenance study results later this quarter. Retaining 75% to 80% of initial weight loss on monthly or every-other-week shots would give the company regimens to test in the Phase 3 extension trials.
🐻 Bear Case
Cash Burn Outpaces the 2028 Runway Target
Zante told analysts on the call, "And our guidance remains intact that we have cash into 2028." That claim clashes with the current pace of cash consumption. Even though operating expenses dropped from the first quarter, Viking's cash and short-term investments still fell by $101.3 million in the second quarter, matching the $102.8 million drop in the first quarter.
- Ending cash and short-term investments: $501.7 million, down from $705.7 million at year-end 2025
- Second-quarter cash decline: $101.3 million by our math
- Runway at current pace: 5.0 quarters by our math, ending in the third quarter of 2027
- Maximum burn to reach 2028: $83.6 million per quarter over the next six quarters by our math
To stretch $501.7 million across the six quarters to reach 2028, quarterly cash use must fall by 17.5% by our math. Yet the company is about to start two Phase 3 oral trials and owes manufacturing prepayments to its supplier CordenPharma between 2026 and 2028.
What to watch: the operating cash flow line in the upcoming second-quarter 10-Q filing. An operating cash outflow near $100 million would show that the funding gap ahead of the 2027 Phase 3 readouts remains open.
Compressed Dosing Could Cloud the Third-Quarter Readout
In the third quarter, the San Diego company will report data from its 180-patient Phase 1 maintenance study, which tests whether patients can switch from weekly shots of VK2735 to every-other-week or monthly shots. On the call, Lian revealed a design trade-off in the initial 21-week weight-loss phase: "We compressed the titration blocks in that first 21-week treatment period."
Titration is the gradual step-up in drug dose over time to help patients avoid nausea and vomiting. The study also pushed doses up to 20 milligrams and 22.5 milligrams, higher than the 15-milligram top dose in Phase 2. Stepping up doses faster to reach higher levels risks raising stomach side effects during the first 21 weeks, and Lian noted that a period-by-period side-effect breakdown might not be ready for the initial release.
What to watch: whether the third-quarter release separates side-effect rates between the 21-week ramp-up and the 12-week maintenance phase. Combined numbers with high nausea rates would make it hard to judge if monthly maintenance dosing is well tolerated.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no new data or commentary in the second-quarter release and conference call.
- Ligand Pharmaceuticals license dispute: neither the release nor the call mentioned Ligand's April notice purporting to terminate the license for liver drug VK2809 and rare-disease drug VK0214; the 10-Q legal footnote will show its status.
- Cardiovascular outcomes trial: management still has not outlined a heart-outcomes study for VK2735, which rival obesity drugmakers use to secure insurance coverage; any trial announcement would clarify long-term costs.
- Oral drug competition: oral VK2735 starts Phase 3 in the fourth quarter against rival pills already on the market; Phase 3 dose selection in the fourth quarter will show how Viking positions the tablet.
- VANQUISH-2 patient count: the diabetes obesity trial closed at roughly 1,000 patients against an earlier 1,100 target; baseline demographics at upcoming medical conferences will show the final trial size.
👓 Other Themes
Commercial and Medical Leadership Hires Continue
As its obesity drugs move through late-stage testing, the biotech group is hiring staff for regulatory filings and sales. In the second quarter, Viking appointed Hubert Chen as chief medical officer to oversee clinical trials and regulatory affairs, and after the quarter ended it named former GoodRx executive Dorothy Gemmell to its board. Hiring and consulting drove general and administrative expenses up 16.8% from a year ago to $16.8 million.
💲 Other KPIs
Unpaid bills and accrued clinical expenses rose to $109.5 million by our math ($69.0 million in accounts payable plus $40.5 million in accrued liabilities), up 43.1% from $76.5 million at the end of 2025. Delaying cash payments to vendors cushioned the second-quarter cash balance, meaning those bills will draw down cash in future quarters.
Upfront payments for clinical trials and early-stage studies more than tripled from the first quarter, rising 272.0% from $4.0 million to $15.0 million (and up from $8.1 million at year-end 2025). The jump reflects upfront deposits for the new VK3019 Phase 1 trial and preparations for the fourth-quarter oral Phase 3 studies.
The average share count rose 3.7% from 112.1 million a year ago, and total issued shares reached 116.7 million at quarter end (up from 114.8 million at year-end 2025). Additional paid-in capital increased by $34.7 million from the first quarter by our math, driven by employee stock compensation and ongoing share issuances.
🔮 Guidance
Unchanged. Zante reiterated that the $502 million cash balance will fund the company into 2028 and that quarterly cash burn will taper from current levels. By our math, reaching the start of 2028 (six quarters away) requires average quarterly cash burn to drop by 17.5%, from $101.3 million in the second quarter to $83.6 million or less.
Unchanged. The clinical-stage group still plans to report results from the subcutaneous maintenance dosing study later in the third quarter of 2026. The oral maintenance cohorts of this study remain scheduled for completion in the first half of 2027.
Unchanged. Management kept its target to start two Phase 3 obesity trials for the daily tablet version of VK2735 in the fourth quarter of 2026, following a one-quarter slip from the third quarter to the fourth quarter announced earlier this year.
❓ Key Questions
What was operating cash burn in the second quarter?
The earnings release omits the cash flow statement. Investors need the 10-Q filing to see whether operating cash outflow stayed below the first quarter's $114.0 million or if equity sales offset a larger burn.
Will the maintenance readout separate ramp-up side effects?
Viking compressed the dose ramp-up in the 21-week induction phase and tested higher doses up to 22.5 milligrams. If the initial data release blends induction and maintenance side effects, high early nausea could obscure the maintenance profile.
What is the status of the Ligand license dispute?
Ligand notified Viking in April that it was terminating the license for liver drug VK2809 and rare-disease drug VK0214. Management did not mention the dispute on the call, leaving its legal and financial impact unclear.
When do CordenPharma manufacturing prepayments begin?
Viking agreed to make multi-year capacity prepayments to CordenPharma between 2026 and 2028. How those scheduled cash outflows fit inside a tapering quarterly cash burn projection remains unexplained.